Avantor Inc Dossier
|
SectorHealth Care IndustryMedical Instruments & Supplies Beta (adjusted)0.94 Intrinsic Value $18.83median of 3 methodsbased on filings through 31 Mar 2026 Market Price $15.05Price as of 30 Sep 2026 UndervaluedIntrinsic value is 25% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $10.2B Enterprise Value $13.7B Shares Outstanding 675M diluted Moat Rating None Next Earnings Date28 Oct 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Avantor is currently a deep-value turnaround play executing its multi-year 'Revival' program to achieve $400 million in cost savings, optimize its portfolio, and reduce elevated leverage. While Q1 2026 results exceeded conservative expectations with an adjusted EPS of $0.17, the core business remains in contraction with organic revenue declining 4.1% year-over-year. Management has designated 2026 as a transitional year of purposeful investment, expecting EBITDA margins to contract by 100 to 150 basis points before recovering in 2027. Given the high execution risk of the turnaround, persistent customer destocking, and a leverage ratio of 3.3x adjusted EBITDA, a Hold rating is maintained until clear signs of organic top-line acceleration and margin stabilization emerge. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$12.00 Mean target$14.56 High · most bullish analyst$19.00 Street targets sit below today's price; our intrinsic value sits above it. Different horizons, different questions. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $12.00 Turnaround execution stalls, and persistent biopharma funding constraints prolong customer destocking. EBITDA margins contract beyond the guided 150 basis points due to inflation and unfavorable product mix. Elevated leverage remains above 3.3x, limiting financial flexibility and causing further multiple compression. Base CaseCentral scenario $14.56 Matches the consensus meanAvantor achieves its reaffirmed FY 2026 guidance with organic revenue growth of -2.5% to -0.5%, adjusted EPS of $0.77 to $0.83, and free cash flow of $500 million to $550 million. Turnaround initiatives show gradual progress, and margins stabilize sequentially in the second half of the year, supporting a modest valuation recovery. Bull CaseUpside scenario $19.00 The 'Avantor Revival' program delivers cost savings ahead of schedule, and bioprocessing order books convert rapidly in the second half of 2026. BMP process chemicals continue double-digit growth, and VWR distribution stabilizes faster than expected in Europe. Deleveraging accelerates below 3.0x, driving multiple expansion toward peer averages. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |